Prinaberel
Systematic (IUPAC) name | |
---|---|
(4Z)-2-fluoro-4-(5-hydroxy-7-vinyl-1,3-benzoxazol-2(3H)-ylidene)-2,5-cyclohexadien-1-one | |
Clinical data | |
Legal status | ? |
Identifiers | |
CAS number | 524684-52-4 |
ATC code | None |
PubChem | CID 5326893 |
ChemSpider | 4484184 |
Chemical data | |
Formula | C15H10FNO3 |
Mol. mass | 271.243 g/mol |
SMILES
| |
| |
Prinaberel (INN, USAN; ERB-041) is a drug which acts as a highly selective agonist of the ERβ subtype of the estrogen receptor.[1] It is used in scientific research to elucidate the role of the ERβ receptor.[2] Studies have indicated that selective ERβ agonists like prinaberel could be useful in the clinical treatment of a variety of medical conditions including inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis.[3] Accordingly, prinaberel either was or still is under investigation by Wyeth for the treatment of some of these conditions.[4]
References
- ↑ Harris HA, Albert LM, Leathurby Y, et al. (October 2003). "Evaluation of an estrogen receptor-beta agonist in animal models of human disease". Endocrinology 144 (10): 4241–9. doi:10.1210/en.2003-0550. PMID 14500559.
- ↑ Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA (May 2005). "Reflections on the discovery and significance of estrogen receptor beta". Endocrine Reviews 26 (3): 465–78. doi:10.1210/er.2004-0027. PMID 15857973.
- ↑ Harris HA (2006). "Preclinical characterization of selective estrogen receptor beta agonists: new insights into their therapeutic potential". Ernst Schering Foundation Symposium Proceedings (1): 149–61. PMID 17824176.
- ↑ "Prinaberel - Wyeth phase change II, USA (endometriosis)". R & D Focus Drug News. 2006-06-05. Retrieved 2012-05-20.
|